FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to gene therapy methods using the transcription factor 4 FOXP (FOXP4) gene, and can be used in medicine to reduce mammalian body weight. A nucleic acid encoding FOXP4, containing its expression vector, a method for its delivery to mammalian fat deposits, and a method for reducing mammalian body weight are proposed.
EFFECT: invention provides a means for effective reduction of mammalian body weight.
8 cl, 3 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NUCLEIC ACID CONTAINING PRDM16 GENE SEQUENCE FOR REDUCING BODY WEIGHT OF MAMMAL, EXPRESSION VECTOR FOR EXPRESSION IN MAMMALIAN CELLS, METHOD FOR DELIVERY THEREOF AND METHOD FOR REDUCING BODY WEIGHT IN MAMMAL | 2024 |
|
RU2834035C1 |
| MINI-PROTEIN USH2A, NUCLEIC ACID CODING MINI-PROTEIN USH2A, AND EXPRESSION VECTOR FOR GENE THERAPY CONTAINING SAME | 2023 |
|
RU2822884C1 |
| NUCLEIC ACID FOR ALLOTOPIC EXPRESSION OF MT-ND4 GENE | 2023 |
|
RU2809065C1 |
| USING VECTOR FOR REDUCING IMMUNE RESPONSE IN VIRAL DELIVERY OF AIPL1 | 2023 |
|
RU2818342C1 |
| MITOCHONDRIAL LOCALIZATION PEPTIDE, NUCLEIC ACID FOR ALLOTOPIC EXPRESSION OF MT-ND4 GENE CONTAINING ITS EXPRESSION VECTOR AND ITS USE | 2023 |
|
RU2817420C1 |
| VECTORS AND SEQUENCES FOR TREATING DISEASES | 2011 |
|
RU2588667C2 |
| CODON-OPTIMISED HAIPL1-ENCODING NUCLEOTIDE SEQUENCE AND EXPRESSION VECTOR CONTAINING SAID SEQUENCE | 2021 |
|
RU2785621C1 |
| EXPRESSION VECTOR BASED ON ADENO-ASSOCIATED VIRUS CARRYING RECOMBINANT ANTIBODY GENES AND ITS USE FOR PREVENTION OF DISEASES CAUSED BY INFLUENZA A VIRUS AND SARS-CoV-2 VIRUS | 2023 |
|
RU2817792C1 |
| ADENO-ASSOCIATED VIRAL VECTORS FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSIS TYPE IV A | 2019 |
|
RU2794960C2 |
| DOUBLE-STRANDED RNA CAPABLE OF REDUCING EXPRESSION OF MUTANT ALLELE C.607G>A OF HUMAN GNAO1 GENE | 2022 |
|
RU2816137C1 |
